D5180C00009 SOURCE A multicentre randomized double blind placebo controlled Phase 3 study to evaluate the efficacy and safety of Tezepelumab
Clinical Trial Grant
Administered By
Medicine, Pulmonary, Allergy, and Critical Care Medicine
Awarded By
AstraZeneca AB
Start Date
June 8, 2018
End Date
May 31, 2021
Administered By
Medicine, Pulmonary, Allergy, and Critical Care Medicine
Awarded By
AstraZeneca AB
Start Date
June 8, 2018
End Date
May 31, 2021